We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

20 hedge funds and large institutions have $1.78M invested in Moleculin Biotech in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

13% more capital invested

Capital invested by funds: $1.58M → $1.78M (+$204K)

0% more funds holding

Funds holding: 20 → 20 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
20
Holders Change
–
Holders Change %
0%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
+$480K
2
AC
Armistice Capital
New York
+$292K
3
Renaissance Technologies
Renaissance Technologies
New York
+$155K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$146K
5
Truist Financial
Truist Financial
North Carolina
+$65.5K

Top Sellers

Rank Fund Capital Flow
1
CIBC World Market
CIBC World Market
Ontario, Canada
-$170K
2
Citadel Advisors
Citadel Advisors
Florida
-$22K
3
TSS
Two Sigma Securities
New York
-$21K
4
VF
Virtu Financial
New York
-$13K
5
BlackRock
BlackRock
New York
-$5.96K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$647K +$146K +49 +16%
CH
2
CVI Holdings
Delaware
$294K +$480K +161 New
AC
3
Armistice Capital
New York
$179K +$292K +98 New
Renaissance Technologies
4
Renaissance Technologies
New York
$127K +$155K +52 +289%
WIC
5
Whitegate Investment Counselors
New Hampshire
$123K +$38.7K +13 +24%
Truist Financial
6
Truist Financial
North Carolina
$113K +$65.5K +22 +55%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$102K – – –
BlackRock
8
BlackRock
New York
$39K -$5.96K -2 -9%
Northern Trust
9
Northern Trust
Illinois
$39K – – –
Bank of New York Mellon
10
Bank of New York Mellon
New York
$27K – – –
Bank of America
11
Bank of America
North Carolina
$20K – – –
Commonwealth Equity Services
12
Commonwealth Equity Services
Massachusetts
$16K +$14.9K +5 +125%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$14K – – –
RJFSA
14
Raymond James Financial Services Advisors
Florida
$11K – – –
Morgan Stanley
15
Morgan Stanley
New York
$10K – – –
LNWWM
16
Laird Norton Wetherby Wealth Management
California
$8K – – –
PFGIA
17
Patriot Financial Group Insurance Agency
Massachusetts
$2K – – –
ACS
18
Archford Capital Strategies
Illinois
$2K +$2.98K +1 New
APA
19
American Portfolios Advisors
New York
$1.62K – – –
Carson Wealth (CWM LLC)
20
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
GRP
21
Global Retirement Partners
California
$1K – – –
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$1K – – –
IWP
23
Icon Wealth Partners
Texas
$1K +$2.98K +1 New
CIBC World Market
24
CIBC World Market
Ontario, Canada
– -$170K -72 Closed
Citadel Advisors
25
Citadel Advisors
Florida
– -$22K -10 Closed
1
2

MBRX Hedge Fund Activity: Q1 2019 in Review

20 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2019, worth a combined $1.78M — up 13% from $1.58M a quarter earlier.

Fund positioning in MBRX was balanced in Q1 2019: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 1 trimmed.

The largest buyer was CVI Holdings, opening a new position worth an estimated $480K. The largest seller was CIBC World Market, exiting entirely with an estimated $170K sold.

  • 20 institutional investors held Moleculin Biotech (MBRX) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $1.78M of Moleculin Biotech stock for Q1 2019, up 13% quarter-over-quarter.
  • 4 funds opened new Moleculin Biotech positions in Q1 2019 and 4 closed out, a net change of 0 holders.
  • The largest Moleculin Biotech buyer in Q1 2019 was CVI Holdings, an estimated $480K added.
  • The largest Moleculin Biotech seller in Q1 2019 was CIBC World Market, an estimated $170K sold.

Based on aggregated 13F filings for Q1 2019.